Angiotensin 1/2 (5-7): Mechanistic Insights for Vasoconstrictor and RAS Research

Executive Summary: Angiotensin 1/2 (5-7) is a tripeptide hormone (H2N-Ile-His-Pro-OH) derived from angiotensinogen and is a potent vasoconstrictor, elevating blood pressure via the renin-angiotensin system (RAS) [Product Sheet]. It is highly soluble in DMSO (≥36.5 mg/mL), ethanol (≥50 mg/mL), and water (≥50 mg/mL), supporting a wide range of laboratory workflows. The peptide enhances SARS-CoV-2 spike protein binding to AXL, implicating it in viral pathogenesis (Oliveira et al., 2025). Purity is confirmed at 98.36% by HPLC and identity by mass spectrometry. It is integral for cardiovascular, hypertension, and infectious disease research.

Biological Rationale

Angiotensin 1/2 (5-7) is a biologically active oligopeptide resulting from the enzymatic processing of angiotensinogen, a serum globulin synthesized in the liver (Oliveira et al., 2025). The peptide sequence H2N-Ile-His-Pro-OH is produced via N-terminal cleavage from longer angiotensin forms. As a prominent member of the renin-angiotensin system (RAS), this peptide contributes to the regulation of vascular tone and systemic blood pressure [ApexBio Product]. Angiotensin 1/2 (5-7) exhibits vasoconstrictor activity, directly influencing smooth muscle contraction within blood vessels. Additionally, recent studies highlight its role in enhancing the binding of the SARS-CoV-2 spike protein to the AXL receptor, suggesting a mechanistic intersection between cardiovascular and infectious disease pathways (Oliveira et al., 2025).

Mechanism of Action of Angiotensin 1/2 (5-7)

The mechanism by which Angiotensin 1/2 (5-7) exerts its biological effect is grounded in the RAS cascade. Angiotensinogen is cleaved by renin to yield angiotensin I, which is further processed by angiotensin-converting enzyme (ACE) and other peptidases to generate active fragments, including angiotensin (1–7) and its N-terminally truncated forms such as angiotensin (5–7) (Oliveira et al., 2025). Angiotensin 1/2 (5-7) binds to angiotensin II receptor subtypes, modulating vasoconstriction and dipsogenic (thirst-inducing) effects. Notably, N-terminally truncated peptides like angiotensin (5-7) display enhanced ability to facilitate SARS-CoV-2 spike protein binding to the AXL receptor, a process independent of the canonical ACE2 pathway (Figure 1, Oliveira et al., 2025).

Evidence & Benchmarks

• Angiotensin 1/2 (5-7) is a tripeptide with the sequence Ile-His-Pro and a molecular weight of 365.43 Da, confirmed by mass spectrometry and HPLC (purity 98.36%) (ApexBio).
• It is highly soluble in DMSO (≥36.5 mg/mL), ethanol (≥50 mg/mL), and water (≥50 mg/mL), enabling versatile experimental applications (ApexBio).
• Angiotensin (5–7) increases SARS-CoV-2 spike protein binding to AXL by over twofold in antibody-based assays (Oliveira et al., 2025, Table 1).
• Unlike angiotensin I (1–10), shorter C- and N-terminal truncated peptides such as angiotensin (5–7) have pronounced effects on spike–AXL interactions (Oliveira et al., 2025).
• Angiotensin 1/2 (5-7) induces potent vasoconstriction in ex vivo vascular tissue models (Angiotensin 1/2 (5-7): A Vasoconstrictor Peptide).

Applications, Limits & Misconceptions

Angiotensin 1/2 (5-7) is central to experimental models investigating blood pressure regulation, hypertension, and RAS-mediated viral pathogenesis. It enables high-precision dissection of angiotensin signaling, especially in contexts where receptor-specific effects need to be isolated. The peptide is also valuable in virology, as it modulates SARS-CoV-2 spike–AXL interactions, offering a unique handle on host-pathogen dynamics (Oliveira et al., 2025).

This review extends prior analyses by mapping the specific spike–AXL enhancement capacity of angiotensin (5–7), providing a direct quantitative framework for RAS and COVID-19 studies. For example, "Angiotensin 1/2 (5-7): Precision Peptide for Hypertension..." discusses hypertension applications, while this article details viral pathogenesis mechanisms. Similarly, "Angiotensin 1/2 (5-7): Precision Tools for Hypertension..." focuses on dual cardiovascular-infectious workflows; this article adds mechanistic evidence from recent peer-reviewed studies.

Common Pitfalls or Misconceptions

• Angiotensin 1/2 (5-7) is not suitable for long-term solution storage; peptide stability declines rapidly at room temperature or above –20°C.
• The peptide does not mimic the full spectrum of angiotensin II (1–8) physiological actions, as its receptor affinity and signaling profile are distinct.
• It will not directly inhibit SARS-CoV-2 infection; rather, it enhances spike–AXL binding and should not be misconstrued as an antiviral agent.
• Effects seen in vitro (e.g., in cell or tissue models) may not directly translate to in vivo outcomes without further validation.
• Experimental solubility should always be confirmed in the specific solvent and buffer conditions used.

Workflow Integration & Parameters

Angiotensin 1/2 (5-7) is provided as a solid, with recommended storage at –20°C. For lab workflows, prepare fresh solutions at concentrations up to 36.5 mg/mL in DMSO, or up to 50 mg/mL in water or ethanol. Avoid repeated freeze–thaw cycles and use solutions promptly to maintain peptide integrity [A1049 kit handling]. Quality control includes batch-specific HPLC purity (>98%) and mass spectrometry identity confirmation. For RAS research, it supports protocols ranging from vascular tissue contraction assays to viral spike–receptor binding studies.

Shipping is performed on blue ice, ensuring temperature stability for small molecule and peptide deliveries. For optimal reproducibility, researchers should follow batch-specific certificates of analysis and validate peptide activity under their own experimental conditions.

Conclusion & Outlook

Angiotensin 1/2 (5-7) (A1049) is a rigorously characterized vasoconstrictor peptide hormone central to RAS and SARS-CoV-2 research. Its solubility profile and mechanistic specificity make it a gold standard for hypertension and viral pathogenesis workflows. Ongoing developments may further elucidate its receptor interactions and potential as a tool for dissecting host-pathogen interfaces. For further product details, see the Angiotensin 1/2 (5-7) product page.